Michael J. Spinella
Affiliations: | Dartmouth College, Hanover, NH, United States |
Area:
Pharmacology, Molecular BiologyGoogle:
"Michael Spinella"Children
Sign in to add trainee| Joshua C. Curtin | grad student | 2004 | Dartmouth |
| Joanna S. Kerley-Hamilton | grad student | 2005 | Dartmouth |
| Kelly C. Heim | grad student | 2009 | Dartmouth |
| Pingping Mao | grad student | 2015 | Dartmouth |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Nelczyk AT, Ma L, Gupta AD, et al. (2022) The nuclear receptor TLX (NR2E1) inhibits growth and progression of triple- negative breast cancer. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 166515 |
| Singh R, Fazal Z, Bikorimana E, et al. (2021) Reciprocal epigenetic remodeling controls testicular cancer hypersensitivity to hypomethylating agents and chemotherapy. Molecular Oncology |
| Albany C, Spinella MJ, Adra N, et al. (2020) A phase I study of guadecitabine (SGI-110) plus cisplatin in patients with platinum refractory germ cell tumors. Journal of Clinical Oncology. 38: 408-408 |
| Tripathi SK, Pandey K, Panda M, et al. (2019) The potential of retinoids for combination therapy of lung cancer: updates and future directions. Pharmacological Research. 104331 |
| Singh R, Fazal Z, Corbet AK, et al. (2019) Epigenetic Remodeling through Downregulation of Polycomb Repressive Complex 2 Mediates Chemotherapy Resistance in Testicular Germ Cell Tumors. Cancers. 11 |
| Singh R, Fazal Z, Bikorimana E, et al. (2019) Abstract 5188: Epigenetic changes mediated by polycomb repressive complex 2 are associated with cisplatin acquired resistance in testicular germ cell tumor Cancer Research |
| Hashemi-Sadraei N, Einhorn LH, Perkins S, et al. (2018) Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b study. Journal of Clinical Oncology. 36: e16545-e16545 |
| Chovanec M, Taza F, Kalra M, et al. (2017) Incorporating DNA Methyltransferase Inhibitors (DNMTis) in the Treatment of Genitourinary Malignancies: A Systematic Review. Targeted Oncology |
| Yim CY, Bikorimana E, Khan E, et al. (2017) G0S2 represses PI3K/mTOR signaling and increases sensitivity to PI3K/mTOR pathway inhibitors in breast cancer. Cell Cycle (Georgetown, Tex.). 1-10 |
| Albany C, Hever-Jardine MP, von Herrmann KM, et al. (2016) Refractory testicular germ cell tumors are highly sensitive to the second generation DNA methylation inhibitor guadecitabine. Oncotarget |